Drug Profile


Alternative Names: SHAPE; SHP-141; SHP-141C; Suberohydroxamic acid phenyl ester (SHAPE)

Latest Information Update: 12 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Dana-Farber Cancer Institute; Harvard University
  • Developer Medivir AB; Shape Pharmaceuticals
  • Class Antineoplastics; Benzoic acids; Small molecules
  • Mechanism of Action Histone deacetylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Cutaneous T cell lymphoma
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Cutaneous T cell lymphoma
  • Discontinued Plaque psoriasis

Most Recent Events

  • 12 Jun 2017 Stanford University plans a phase II trial for Basal cell cancer in USA (NCT03180528)
  • 07 Apr 2017 Additional efficacy data from a phase II trial in Cutaneous T cell lymphoma released by Medivir
  • 07 Apr 2017 Medivir completes a phase II trial in Cutaneous T cell lymphoma (Early-stage disease) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top